Needham Maintains Buy on Hims & Hers Health, Lowers Price Target to $32
Benzinga Newsdesk 3 hours ago
Analyst RatingsNewsPrice Target
Needham analyst Ryan MacDonald maintains Hims & Hers Health (NYSE:HIMS) with a Buy and lowers the price target from $42 to $32.
Needham analyst Ryan MacDonald maintains Hims & Hers Health (NYSE:HIMS) with a Buy and lowers the price target from $42 to $32.